StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) bonds

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)

Close on Nov 18, 2026Market cap $4.74BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Travere Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Travere Therapeutics's 10-Q for the period ended Jun 30, 2026

IssueCouponMaturesAmount issuedCarrying value
Senior Notes Due 2029
Convertible at $32 a share
2.25%2029–$94.88M
Senior Notes Due 2029, Issued Pursuant to Underwriters Option–2029–$41.30M
Senior Notes Due 2032
Convertible at $65 a share
0.50%2032$525.00M$525.00M
Senior Notes Due 2032, Issued Pursuant To Underwriters Option–2032$50.00M–

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

See a number that looks wrong?